Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PBMs Under Medicare: Avoiding Risk May Be Risky Strategy

Executive Summary

Pharmacy benefit management companies will offer at-risk stand-alone Medicare prescription drug plans under the new Part D benefit, former Centers for Medicare & Medicaid Services Administrator Tom Scully told the Medco drug trend symposium in Lake Buena Vista, Fla. May 18

You may also be interested in...



Medco Without Merck: Generics At Mail Are Key To Profitability

Mail service delivery of generic drugs is emerging as the key to Medco's profitability

Medco “Fallback” Comments Create Fallout On Capitol Hill

Medco and other pharmacy benefit managers that have said they will not offer a Part D prescription drug plan should wait to see the implementing regulations before making a decision, Centers for Medicare & Medicaid Services Senior Policy Advisor Tim Trysla said

Medco Without Merck: Generics At Mail Are Key To Profitability

Mail service delivery of generic drugs is emerging as the key to Medco's profitability

Related Content

UsernamePublicRestriction

Register

PS044079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel